Subtle issues in model specification and estimation of marginal structural models

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 3, 2012, Pages 241-245

  Yang, Wei ^a   Joffe, Marshall M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONOTHERAPY; CONFOUNDING VARIABLE; EXPERIMENTAL MODEL; HEART FAILURE; HUMAN; INTENTION TO TREAT ANALYSIS; MARGINAL STRUCTURAL MODEL; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL;

ANGIOTENSIN RECEPTOR ANTAGONISTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; FEMALE; HEART FAILURE; HUMANS; LOSARTAN; MALE; TETRAZOLES; VALINE;

EID: 84862827429     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2306     Document Type: Note

References (12)

1. Brumback BA, Hernan MA, et al. Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures. Stat Med 2004; 23(5): 749-767.
2. Desai RJ, Ashton CM, et al. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure: a marginal structural model approach. Pharmacoepidemiol Drug Saf 2011; 21(3): 233-240.
3. Hernan MA, Alonso A, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008; 19(6): 766-779.
4. Imai K, van Dyk DA. Causal inference with general treatment regimes: generalizing the propensity score. J Am Stat Assoc 2004; 99(467): 854-866.
5. Joffe MM, Ten Have TR, et al. Model selection, confounder control, and marginal structural models: review and new applications. American Statistician 2004; 58(4): 272-279.
6. Mark SD, Robins JM. Estimating the causal effect of smoking cessation in the presence of confounding factors using a rank preserving structural failure time model. Stat Med 1993; 12(17): 1605-1628.
7. Pearl J. Causality: models, reasoning, and inference. Cambridge University Press: Cambridge, U.K.; New York, 2000.
8. Robins J. A new approach to causal inference in mortality studies with a sustained exposure period--application to control of the healthy worker survivor effect. Mathematical Modelling 1986; 7(9-12): 1393-1512.
9. Robins JM, Blevins D, et al. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology 1992; 3(4): 319-336.
10. Robins JM, Hernan MA, et al. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11(5): 550-560.
11. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70(1): 41-55.
12. van der Laan MJ, Petersen ML, et al. History-adjusted marginal structural models and statically-optimal dynamic treatment regimens. The International Journal of Biostatistics 2005; 1(1): Article 4.